|
Delayed
Nasdaq Stockholm
20:00:00 15/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.280 SEK | +4.59% |
|
+2.70% | +0.88% |
| 08-20 | Lärkberget AB Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-21 | Larkberget to carry out rights issue of units totaling SEK 14.9 mln | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 4.62M | - | - | - | - | - |
| 69.18B | |||||
| 62B | |||||
| 26.19B | - | ||||
| 25.75B | |||||
| 24.29B | - |
- Stock Market
- Stocks
- LARK Stock
- Charts CombiGene AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
